Fresenius Medical Care AG (Fresenius Medical Care AG) Cash And Cash Equivalents : $1,531 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Fresenius Medical Care AG Cash And Cash Equivalents?

Fresenius Medical Care AG's quarterly cash and cash equivalents increased from Jun. 2023 ($1,474.86 Mil) to Sep. 2023 ($1,657.69 Mil) but then stayed the same from Sep. 2023 ($1,657.69 Mil) to Dec. 2023 ($1,530.53 Mil).

Fresenius Medical Care AG's annual cash and cash equivalents declined from Dec. 2021 ($1,674.19 Mil) to Dec. 2022 ($1,349.35 Mil) but then increased from Dec. 2022 ($1,349.35 Mil) to Dec. 2023 ($1,530.53 Mil).

Fresenius Medical Care AG Cash And Cash Equivalents Historical Data

The historical data trend for Fresenius Medical Care AG's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius Medical Care AG Cash And Cash Equivalents Chart

Fresenius Medical Care AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

1,119.69

1,315.74

1,674.19

1,349.35

1,530.53

Fresenius Medical Care AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															1,349.35	1,310.38	1,474.86	1,657.69	1,530.53

Fresenius Medical Care AG Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Fresenius Medical Care AG (NYSE:FMS) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Fresenius Medical Care AG Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Fresenius Medical Care AG's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresenius Medical Care AG (Fresenius Medical Care AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius Medical Care AG (NYSE:FMS) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

FMCQF:USA FME:Italy FMEd:UK 0H9X:UK FME:Germany FMEA:Germany FME:Germany FME:Germany FMEA:Germany FME:Germany FMSC34:Brazil FME:Austria

Address

Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352

Website

https://www.freseniusmedicalcare.com

Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Executives

Helen Pring Giza

Board of Directors